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Background. The replication of BK virus (BKV) and JC virus (JCV) is linked to polyomavirus-associated ne-
phropathy, hemorrhagic cystitis, andmultifocal leukoencephalopathy in immunodeficient patients, but the behavior
of these viruses in immunocompetent individuals has hardly been characterized.
Methods. Weused EIA to study samples obtained from 400 healthy blood donors aged 20–59 years for BKV- and
JCV-specific antibodies against virus-like particles. We also studied BKV and JCV loads in plasma and urine among
these individuals by use of real-time polymerase chain reaction.
Results. IgG seroprevalencewas 82% (328 of 400 donors) for BKVand 58% (231 of 400) for JCV.As age increased
(age groups were divided by decade), the seroprevalence of BKV decreased from 87% (87 of 100) in the youngest
group (aged 20–29 years) to 71% (71 of 100) in the oldest group (aged 50–59 years) (P  .006), whereas the
seroprevalence of JCV increased from 50% (50 of 100) in the youngest group to 68% (68 of 100) in the oldest group
(P  .06). Asymptomatic urinary shedding of BKV and JCV was observed in 28 (7%) and 75 (19%) of 400 subjects,
respectively, with median viral loads of 3.51 and 4.64 log copies/mL, respectively (P  .001). Unlike urinary BKV
loads, urinary JCV loads were positively correlated with IgG levels. The shedding of JCV was more commonly
observed among individuals who were seropositive only for JCV, compared with individuals who were seropositive
for both BKV and JCV, suggesting limited cross-protection from BKV immunity. Noncoding control regions were of
archetype architecture in all cases, except for 1 rearranged JCV variant. Neither BKV nor JCV DNA was detected in
plasma.
Conclusions. Our study provides important data about polyomavirus infection and replication in healthy, im-
munocompetent individuals. These data indicate significant differences between BKV and JCV with respect to virus-
host interaction and epidemiology.
The human polyomaviruses BK (BKV) and JC (JCV)
infect immunocompetent individuals without specific
signs or symptoms and remain latent thereafter in the
renourinary tract [1]. In seropositive individuals with
altered immunity, viral replication can reactivate and
progress to serious organ diseases such as polyomavirus-
associated nephropathy, hemorrhagic cystitis, and pro-
gressivemultifocal leukoencephalopathy [2–4]. Because
no specific antiviral drugs are available to treat polyoma-
virus disease, treatment depends on improving immune
functions to regain control over viral replication [5].
Polyomavirus-associated nephropathy (PVAN) in in-
dividuals who have undergone kidney transplantation is
primarily caused by BKV replication , with rates ranging
from 1%–10% [6, 7]. The stringent sequence of high-
level viruria of 7 log genome equivalents (GEq)/mL
followed by viremia and histologically manifest disease
after transplantation has become a paradigm of poly-
omavirus pathogenesis and diagnosis [8, 9]. The dynam-
ics of BKV replication are rapid, with a half-life of 2 h–12
h in plasma and urine [10, 11]. The extensive cytopathic
wear of 4  107 cells per day is further accelerated by
more pathogenic BKV variants with rearranged non-
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coding control regions (NCCRs) that increase viral replication
capacity [12].
High-level urothelial BKV replication is also observed in
50%of patients after hematopoietic stem-cell transplantation,
but only 10% develop severe polyomavirus-associated hemor-
rhagic cystitis [13, 14]. The key JCV-mediated disease is progres-
sive multifocal leukoencephalopathy, which was diagnosed in
7% of patients with HIV or AIDS prior to the advent of com-
bined antiretroviral therapy [15–17]. JCV viruria seems not to
correlate with histologically confirmed JCV disease, and JCV vi-
remia is exceptional and low level [18–21].
The behavior of BKV and JCV in immunocompetent individ-
uals has hardly been investigated, and some results seem contra-
dictory. Ling et al. detected JCV but not BKV in urine, and pe-
ripheral blood mononuclear cells (PBMCs) were uniformly
negative for both viruses [22]. By contrast, Dolei et al. reported
detecting BKV and JCV DNA in 7% and 0.9%, respectively, of
231 DNA preparations of PBMCs from healthy blood donors
[23]. Zhong et al. detected BKV and JCVDNA in centrifugation-
enriched urine pellets from 351 presumably immunocompetent
outpatients and 99 healthy volunteers, and the percentage of
subjects in whom the viruses were detected increased with age,
from 14% to 44% and 10% to 72%, respectively [24]. None of
these studies conducted antibody testing to distinguish between
reactivation and primary replication. Research that used hemag-
glutination inhibition assays (HIA) indicated that the overall
seroprevalence rates were 81% for BKV and 35% for JCV, but
urinary viral shedding was not investigated [25]. Thus, there is
considerable uncertainty about the BKV and JCVdetection rates
and the viruses’ respective seroprevalence. For the analysis of
samples obtained from 400 healthy blood donors at the time of
blood donation, we used current real-time polymerase chain re-
action (PCR) andEIA for antibodies to virus-like particles (VLP)
to identify BKV and JCV DNA in urine and plasma and to de-
termine antibody responses in plasma.
SUBJECTS AND METHODS
Blood donor population. We enrolled 400 consecutive healthy
blood donors from the blood donation center in Basel, Switzerland
(Schweizerisches Rotes Kreuz [Swiss Red Cross]) from February
2007 to January 2008. Participants gave written informed consent
to the protocol (267/06) approved by the local institutional review
board. Participants were enrolled into 1 of 4 age groups of 100 per-
sons each (divided by decade into age 20–29, 30–39, 40–49, and
50–59 years); each group consisted of 50women and 50men (total
in all 4 age groups, 200 men and 200 women). From each partici-
pant, citrate-anticoagulated blood (CPT Vacutainer; Becton Dick-
inson) and urine were collected at the time of regular blood dona-
tion. The donors fulfilled all criteria required for blood donation,
including serologic andPCRnegativity for hepatitis B virus (HBV),
hepatitis C virus (HCV), HIV, and Treponema pallidum.
Polyomavirus molecular diagnostic assays. BKV and JCV
loads were quantified after DNA extraction from citrate-
anticoagulated plasma or urine using the Magnapure reagents
and robotics (Roche). The real-timePCRprotocols for detection
of BKV and JCV DNA in urine and plasma samples have been
described elsewhere [8, 12, 21, 26]; the primers and probes used
are listed in table 1. For the purpose of the study, the limit of
detection was arbitrarily set to 3 log GEq/mL, which is the limit
used routinely in our diagnostic laboratory.
EIA for antibodies toBKand JCVLP. TheVP1 coding sequence
of BKV and JCV was inserted into a pFastBac vector (Invitrogen) by
using the restriction enzymes BamHI-XhoI and BamHI-HindIII
(New England Biolabs). Recombinant baculovirus genomes
containing the BKV or JCVVP1 gene sequence were generated by
using the Bac-to-Bac expression system (Invitrogen) and trans-
fected in Sf 9 insect cells, in accordance with the manufacturer’s
instructions. The 3-dimensional structure and quality of BK VLP
and JCVLPwas confirmedby electronmicroscopy.BKVLPand JC
VLP were used as antigens in a standard EIA assay, as described
elsewhere [27].Theopticaldensityat492nm(OD492)obtainedwith
PBS alone was taken as background and subtracted. The cutoff
definingapositive serologic responsewasOD492 0.110 forBKV-and
JCV-specific IgG and IgM.
Sequencing of viral NCCR and BK VP1 gene. To deter-
mine the architecture of the BKV and JCV NCCRs, we per-
formed nested PCR using BKV- and JCV-specific primer sets
(table 1). The amplicons were analyzed with 2% Tris, sodium
acetate, and EDTA–agarose gel electrophoresis to identify arche-
typal structure, as well as deletions and/or insertions. Bands of
alteredmobility were extracted and sequenced as described else-
where [12]. The BKV serotype-defining VP1 sequences [28]
were identified by cycle sequencing on an AB3130 Genetic Ana-
lyzer, using the primers shown in table 1 .
Statistical analysis. For statistical analysis, we used SPSS
(version 13; SPSS). Data were summarized as medians and
ranges or as mean (SD), as appropriate. If the Kolmogorov-
Smirnov Z Test indicated a nonnormal distribution, we used
nonparametric tests such as Mann-Whitney U tests, Kruskal-
Wallis tests, Spearman’s  correlation analyses, linear regression
analysis, and paired Wilcoxon tests. Categorical data were ana-
lyzed by using Fisher’s exact test or Pearson’s 2 test, depending
on sample size. All tests were 2 sided andP  .05 was considered
statistically significant. Bonferroni correction was used where
appropriate.
RESULTS
General characteristics of the study population. More than
95% of blood donors were white. Their blood and rhesus groups
corresponded to the distribution found in central Europe; group
Awas themost common, observed in 194 (49%) of 400 subjects,
followedby group 0 in 146 subjects (37%), groupB in 23 subjects
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(6%), and group AB in 37 subjects (9%). Of 400 subjects, 331
(83%) were positive for rhesus factor.
Prevalence of BKV and JCV antibodies, DNAemia, and
DNAuria. BKV IgG seroprevalence among healthy blood do-
nors was 82% (328 of 400), significantly higher than the corre-
sponding JCV IgG seroprevalence of 58% (231 of 400) (P  .001,
by2 test; figure 1A). Themean IgG level as defined byOD492 was
higher for BKV than for JCV (P  .001, by Mann-Whitney U
test). No significant difference was detected in IgM seropreva-
lence, which was 1% (4 of 400) for BKV and 0% (0 of 400) for
JCV. All of the IgM-positive individuals were also IgG positive.
BKV was detected in urine samples from 28 (7%) of 400
healthy blood donors, a detection rate lower than that for JCV,
which was detected in samples from 75 (19%) of the donors
(P  .001, by2 test; figure 1B).Median urinary viral loadswere
also lower for BKV than for JCV (3.5 log vs. 4.8 log GEq/mL;
P  .001, by Mann-Whitney U test). Four (1%) of 400 healthy
blood donors had bothBKVand JCVDNAdetected in the urine.
No difference in urinary BKV or JCV load was detectable when
we compared individuals who shed just one of the viruses with
individuals who shed both viruses (table 2). There was no asso-
ciation between polyomavirus shedding and ABO blood group.
However, individuals who shed BKV in the urine were more
likely to be positive for rhesus factor thanwere thosewho did not
(27 of 331 vs. 1 of 69; P  .047, by 2 test), whereas no associa-
tion between rhesus factor positivity and JCV shedding was
found (60 of 331 vs. 15 of 69; P  .484, by 2 test). Of note,
neither BKVnor JCVDNAwas detected in any of the 400 plasma
samples.
Sex and age dependent prevalence of BKV and JCV anti-
bodies and viruria. BKV IgG seroprevalence was not different
between femaleandmaleblooddonors (165[83%]vs.163[82%]of
200;P  .795, by 2 test) (figure 1C). However, the level of BKV
IgG activity was higher for women than for men (P  .025, by
Mann-Whitney U test). No difference in JCV IgG seropreva-
lence or the level of JCV IgG activity was apparent between
women and men (113 [57%] of 200 vs. 118 [59%] of 200;
P  .613, by 2 test; P  .451, by Mann-Whitney U test) (fig-
ure 1C). Both BKV and JCV were more frequently detected in
urine samples obtained from men, compared with samples ob-
tained from women (P  .05 for BKV and .007 for JCV, by 2
test) (figure 1D). However, there were no significant differences
between the sexes with respect to urinary BKV or JCV loads
(figure 1D).
When we compared the antibody responses in the different
age groups, we found that IgG seroprevalence and the level of
Table 1. Primers and probes used for detection of BK and JC polyomavirus (BKV and JCV)
in plasma and urine from 400 healthy blood donors.
Analysis Sequence
PCR quantification
BKV
LT-forward 5'-AGCAGGCAAGGGTTCTATTACTAAAT-3'
LT-reverse 5'-GAAGCAACAGCAGATTCTCAACA-3'
Probe FAM-AAGACCCTAAAGACTTTCCCTCTGATCTACACCAGTTT-TAMRA
JCV
LT-forward 5'-CTAAACACAGCTTGACTGAGGAATG-3'
LT-forward 5'-CATTTAATGAGAAGTGGGATGAAGAC-3'
Probe FAM-TAGAGTGTTGGGATCCTGTGTTTTCATCATCACT-TAMRA
NCCR rearrangement
BKV
Outer 1, BKTT5 5'-GAGCTCCATGGATTCTTC-3'
Outer 2, BKTT6 5'-CCAGTCCAGGTTTTACCA-3'
Inner 1, BKTT7 5'-CCCTGTTAAGAACTTTATCCATTT-3'
Inner 2, BKTT8 5'-AACTTTCACTGAAGCTTGTCGT-3'
JCV
Outer 1 5'-AGGCCTAATAAATCCATAAGCTCCA-3'
Outer 2 5'-GTTCCACTCCAGGTTTTACTAACTT-3'
Inner 1 5'-TTTTAGCTTTTTGCAGCAAAAAATTA-3'
Inner 2 5'-CCTGGCGAAGAACCATGGCCAG-3'
BKV VP1 sequencing
Outer 1 5'-GTGCAAGTGCCAAAACTACTAATAA-3'
Outer 2 5'-TGCATGAAGGTTAAGCATGCTAGT-3'
Inner 1 5'-CAACCAAAAGAAAAGGAGAGTGTC-3'
Inner 1 5'-TCCTCCACCATGCTCATGCACT-3'
NOTE. LT, large T antigen; NCCR, noncoding control region; PCR, polymerase chain reaction.
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BKV IgG activity decreased significantly with increasing age,
from 87% (87 of 100) in the youngest group (aged 20–29 years)
to 71% (71 of 100) in the oldest group (aged 50–59 years)
(P  .006; figure 2A), whereas a strongly opposite trend was
found for JCV IgG (P  .06) (figure 2A). BKV sheddingwas not
associated with age group (P  .429, by 2 test) (figure 2B). By
contrast, JCV shedding was more frequent in older age groups,
increasing from 9% (9 of 100) in the youngest group to 28% (28
of 100) in the oldest group (P  .02, by 2 test), but no correla-
tion between age and urinary viral load was found (figure 2B).
When we compared individuals who shed just one virus with
thosewho shed both viruses, we found that individuals who shed
only BKV tended to be younger than those who shed only JCV.
All individuals who shed both BKV and JCV belonged to the
oldest age group (50-59 years old).
Serologic responses and viral loads. To investigate the re-
lationship between antibody response and the level of urinary
viral shedding, we divided subjects into the following 3 strata,
according to their urinary viral load: undetectable (3 log GEq/
mL), low (3–6 log GEq/mL), and high (6 log GEq/mL). BKV
loads were undetectable in 372 (93%) of the donors and low in
the remaining 28 (7%). JCV loads were undetectable in 325
(81%), low in 61 (15%), and high in 14 (4%) of the donors
(figure 3). There was no correlation between BKV antibody level
and urinary BKV load. For JCV, the IgG level was significantly
higher in individuals in the high-shedding group, compared
with those in the low-shedding group (P  .001) (figure 3).
Similar results were obtained for JCV by using a Spearman  test
and a linear regression model (Spearman , 0.284 [P  .017];
and linear regression coefficient [R2], 0.139 [P  .001]),
whereas only a trend was observed for BKV (Spearman , 0.423
[P  .027]; and R2, 0.122 [P  .081). No cross-correlation was
found between BKV loads and JCV IgG activity level (data not
shown).
Cross-reactivity of BKV and JCV IgG responses. Seropositivity
for both BKV IgG and JCV IgGwas found in 182 (46%) of 400 indi-
viduals.Whenwecompared the IgGantibody level in individualswho
were seropositive for only one virus with that in individuals whowere
seropositive for both viruses,we found that theBKV IgG levelwas sig-
nificantly higher in individualswhowere seronegative for JCV than in
individuals whowere seropositive for bothBKVand JCV (P  .012;
table 3). Conversely, individuals who were seropositive only for
Figure 1. Box-whisker plots showing overall prevalence of BK and JC polyomavirus (BKV and JCV) antibodies and viruria. A, BK and JC virus-like
particle (VLP)–specific IgG seroprevalence (N  400). B, Urinary BKV and JCV load (N  400). C, BK-VLP–specific and JC-VLP–specific IgG
seroprevalence, according to sex (n  200, for each sex). D, Urinary BKV and JCV load, according to sex (n  200, for each sex). Boxes span the
interquartile range; the line within each box denotes the median, and whiskers indicate the minimum and maximum values. *P calculated by
Mann-Whitney U test; **P calculated by 2 test. GEq, genome equivalents; OD492, optical density at 492 nm.
840 ● JID 2009:199 (15 March) ● Egli et al.
JCV showed a higher JCV IgG level than did those who were
seropositive for both BKV and JCV (P  .028; table 3). When
we compared the rate at which urinary BKV shedding occurred,
we found no difference between individuals who were seropos-
itive for BKV and those who were seropositive for BKV and JCV
(P  .169). Interestingly, urinary shedding of JCV was signifi-
cantly less common among individuals who were seropositive
for both viruses, compared with those who were seropositive
only for JCV (P  .001; table 3). When we compared the BKV
IgG level and the JCV IgG level, we found no positive correlation
(figure 4A). By contrast, some limited correlation suggestive of
cross-reactivity was apparent between BKV and JCV IgM activ-
ity levels (figure 4B). Taken together, these data indicated that
BK-VLP and JC-VLP IgG responses were specific to the respec-
tive polyomavirus capsid and that cross-reactivity was not a ma-
jor concern.
Types of BKV detected in urine. To investigate the serotype-
defining genotype of BKV in the urine of healthy blood donors, we
sequenced the relevant VP1 region. Although urinary BKV loads
were low, 25 of 28 samples positive for BKV by PCR could be se-
quenced. BKV type 1 wasmost common, occurring in 18 (80%) of
25 samples, followed by type 4 (in 5 samples [20%]), and type 2 (in
2 samples [8%]). BKV type 3 was not found. No differences inme-
dian urinary BKV loads were found between the subtypes (theme-
dian [range] BKV load for type 1 was 3.57 log GEq/mL [3.0–4.8
GEq/mL], for type2 itwas3.27GEq/mL[3.0–4.2GEq/mL]and for
type 4, it was 3.27 GEq/mL [3.2– 3.8 GEq/mL]). When we com-
pared the BKV IgG level in individuals who shed BKV, we found a
significantly higher BKV IgG level in individuals who shed BKV
type 1, compared to those who shed non-type 1 BKV (figure 4C).
When the BKV IgG level among the 18 individuals who shed BKV
type 1 was compared according to viral subtype (i.e., subtypes 1a
[n  5)], 1b-1 [n  6], and 1b-2 [n  7]), it showed a trend
toward increase among patients who shed BKV subtype 1-b2
(figure 4D).
Architecture of BKV and JCV NCCR in subjects who shed
virus. Given the role the polyomavirus NCCR plays in viral
replication capacity in transplant recipients, we examined the
NCCR architecture of BKV and JCV found in the urine of
healthy blood donors. In 20 of 28 BKV-positive urine samples,
the NCCR could be amplified and sequenced but no NCCR re-
arrangement was identified. In 70 of 75 JCV-positive urine sam-
ples, the NCCR could be characterized, and in only 1 case was a
rearranged JCV NCCR was identified. The JCV NCCR rear-
rangement was confirmed in 2 subsequent urine samples ob-
tained 1 and 2 months after the original sample, which revealed
identical insertion in the F-block (GeneBank accession numbers
FJ233068–70). In the first sample, the urinary JCV load was 4.78
log GEq/mL; in the second, it was 3.78 log GEq/mL; and in the
third, it was 3.25 log GEq/mL.
DISCUSSION
This comprehensive study of samples from 400 consecutive
blood donors provides important baseline data on human poly-
omavirus infection and replication. First, the overall IgG sero-
prevalence for BKV was 82% (328 of 400), which was signifi-
cantly higher than the 58% (231 of 400) seroprevalence observed
for JCV. Second, urinary shedding of BKV was observed in 28
subjects (7%), which was significantly fewer than the 75 subjects
(19%) observed to shed JCV. Third, the median urinary BKV
load was 3.51 log GEq/mL, which was significantly lower than
the median urinary JCV load of 4.64 log GEq/mL. Fourth, anal-
ysis of the NCCR of all urinary BKV and JCV genomes revealed
archetype architecture in all but 1 case, which involved a rear-
ranged JCV NCCR. Finally, neither BKV nor JCV was detected
Table 2. Age and viral status of blood donors evaluated for BK and JC polyomavirus (BKV and JCV), according to virus detected.
BKV and JCV
(n  4)
BKV only
(n  24)
JCV only
(n  71)
None
(n  301) P
Demographic characteristic
Age, median (range), years 55 (53–56) 39 (22–58) 46 (20–59) 38 (20–59) .001a
Viral data
BKV
VLP-specific IgG, median (range) 0.4415
(0.0974–0.9066)
0.8079
(0.0858–1.7773)
0.3012
(0.0001–1.876)
0.5353
(0.0035–3.2405)
.001a
Urinary viral load, median (range),
GEq/mL
2812 (1020–5660) 3270 (1000–64,900) 0 0 .59b
JCV
VLP-specific IgG, median (range),
OD492
1.2752
(0.1753–2.062)
0.0774
(0.0205–0.9538)
0.6596
(0.0306–2.0533)
0.1101
(0.0035–2.7329)
.001a
Urinary viral load, median (range),
GEq/mL
5,469,450
(31,997–2.1  107)
0 42,251
(1471–32.7  106)
0 .132b
NOTE. GEq, genome equivalents; OD492, optical density at 492 nm; VLP, virus-like particles.
a By Kruskal-Wallis test.
b By Mann-Whitney U test.
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in plasma under conditions routinely used tomonitor viremia in
patients undergoing kidney and/or hematopoietic stem-cell
transplants. Unlike earlier studies, we studied healthy donors at
the time of regular blood donation that was conducted in accor-
dance with international standards and was not confounded by
pregnancy, clinical and laboratory abnormalities, or infections
with T. pallidum, HIV, HBV, or HCV. Thus, we may conclude
that BKV and JCV infection and replication are common in
bona fide healthy, immunocompetent adults, but the rates of
seropositivity and urinary viral shedding point to significant dif-
ferences in the epidemiology of BKV and JCV infection.
We noted that the BKV IgG seroprevalence was highest in the
youngest age group (aged 20–29 years) at 87% (87 of 100) and
decreased with older age to 71% (71 of 100) in the oldest group
(aged 50–59 years), whereas the opposite trendwas observed for
JCV IgG seroprevalence, which increased from 50% (50 of 100)
in the youngest group to 68% (68 of 100) in the oldest group.
Knowles et al. [25] used HIA in a large study of 2435 serum
samples obtained in England in 1991 and observed a similar
age-related decrease in BKV seroprevalence from 91% to 74%
(P  .01; overall mean seroprevalence, 81%), whereas JCV se-
roprevalence increased with age from 34% to 45% (P  .01;
overall mean seroprevalence, 35%). We may conclude that no
gross alterations in the epidemiology of BKV infection seem to
have occurred in the last 15 years. Similar data have been re-
ported for immunocompetent Japanese outpatients [24]. The
data indicate that the puzzling increase in the incidence of PVAN
is not related to changes in the epidemiology of BKV infection in
Figure 2. Box-whisker plots showing age-dependant prevalence of BK and JC polyomavirus (BKV and JCV) antibodies and viruria. A, BK and JC
virus-like particle (VLP)–specific IgG levels, according to age group. B, Urinary BKV and JCV load, according to age group. Boxes span the interquartile
range; the line within each box denotes the median, and whiskers indicate the minimum and maximum values. *P calculated by Kruskal-Wallis test;
**P calculated by 2 test. GEq, genome equivalents; OD492, optical density at 492 nm.
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the general population, but rather to other modulating factors,
of which increased immunosuppression following kidney trans-
plantation is the key suspect.
The decline in BKV IgG antibody level with age is also of
interest, as it suggests that significant (re)exposure to BKV does
not seem to occur in most healthy, immunocompetent individ-
uals during adult life. This is in line with our data showing low-
level urinary shedding of BKV in only 28 individuals (7%). By
contrast, significant increases in BKV-specific antibody titers
have been observed in patients undergoing kidney transplanta-
tion who had high-level viruria and viremia [27, 29–33]. Unlike
BKV, JCV starts with a lower IgG seroprevalence that increases
with age. Initial serological studies indicated that BKV infection
occurs earlier during childhood, whereas JCV infection follows
later, which is supported by our data as well. This suggests that
significant exposure to JCV leads to primary and secondary in-
fections during adult life. This observation is of interest for the as
yet unresolved pathogenesis of progressive multifocal leukoen-
cephalopathy in patients with AIDS and suggests the hypothesis
that exogenous infection and replication may be the cause in
some profoundly immunosuppressed individuals.
Our data show that urinary shedding of JCV was not only
more common but occurred in significantly greater quantities
than BKV shedding, with 14 (4%) of 400 participants having
JCV loads 6 log GEq/mL. By contrast, the urinary BKV load
was observed to be5 log GEq/mL for all subjects. Thus, com-
pared to immune control of BKV, JCV-directed humoral and/or
cellular immunity seems less efficient at controlling viral repli-
Figure 3. Box-whisker plots showing virus-like particle (VLP)–specific IgG activity for BK and JC polyomavirus (BKV and JCV), according to urinary
viral load. Subjects were stratified as follows: 3 log genome equivalents (GEq)/mL (undetectable), 3–6 log GEq/mL (low), and 6 log GEq/mL (high).
Boxes span the interquartile range; the line within each box denotes the median, and whiskers indicate the minimum and maximum values. *P calculated
by Mann-Whitney U test; **P calculated by Kruskal-Wallis test. OD492, optical density at 492 nm.
Table 3. IgG activity levels and viral shedding in the urine of 400 healthy blood donors evaluated for BK and
JC polyomavirus (BKV and JCV), according to serologic results.
Viral data
BKV/JCV
(n  23)
BKV/JCV
(n  146)
BKV/JCV
(n  49)
BKV/JCV
(n  182) P
VLP-specific IgG, OD492
BKV 0.0586
(0.0035–0.1002)
0.7709
(0.1141–3.2405)
0.0776
(0.0001–0.1065)
0.5241
(0.1142–2.6862)
.012a
JCV 0.0398
(0.0035–0.094)
0.0523
(0.0059–0.1085)
0.6096
(0.1144–2.0533)
0.4343
(0.1101–2.7329)
.028b
Virus detected in urine,
proportion of subjects
BKV 0/23 15/146 2/49 11/182 .169c
JCV 0/23 4/146 19/49 52/182 .001c
NOTE. OD492, optical density at 492 nm; VLP, virus-like particle.
a Comparison of BKV/JCV and BKV/JCV, by Mann-Whitney U test.
b Comparison of BKV/JCV and BKV/JCV, by Mann-Whitney U test.
c Comparison of individuals who shed virus, by 2 test.
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cation. The absence of IgM in practically all individuals who
shed virus indicates that these events represent persistent or re-
activated replication. Given the role of cellular immune control
in other viral infections that have a propensity for latency and
reactivation, such as cytomegalovirus infection, we suspect that
these differences most likely reside in the efficiency of cellular
immune surveillance [7, 34]. However, BKV and JCV are closely
related to each otherwith 72%–81%nucleotide homology in the
regions of the 5.1-kb DNA genome, yielding amino acid homol-
ogies of 59%–83% [35]. We observed that JCV shedding was
significantly more common among individuals who were posi-
tive only for JCV, compared with those who were seropositive
for both BKV and JCV, suggesting limited cross-protection from
a BKV-induced immune response. A precedent for limited
cross-protection has been established for herpes simplex type 1
and type 2, which are 	70% homologous to one another [36].
Moreover, cross-reacting CD8 T cells have been described re-
cently for some closely related peptide epitopes in the large T
antigen and in the VP1 capsid protein [37–39]. Because T cell
immunity requires major histocompatibility complex presenta-
tion by infected cells or processing by antigen-presenting cells,
we suspect that JCV shedding is not necessarily a sign of T cell
dysfunction but may instead reflect differences between BKV-
and JCV-infected cells with respect to presentation, anatomic
location, and/or accessibility toT cells (e.g., inmucosal sites) [6].
Our data suggest that male sex and older age may be contribu-
tory factors. In this respect, Drachenberg et al. noted that reduc-
ing immunosuppression in patients undergoing kidney trans-
plantation who had JCV-mediated PVAN resulted in clearance
of allograft involvement but not clearance of urinary JCV loads
[21]. Clearly, further studies are needed to address these differ-
ences in the respective polyomavirus-host balance.
Our serological analysis indicated that there is little cross-
reactivity between BKV and JCV IgG when baculovirus-expressed
VLP are used as EIA antigens. This result is in linewithVLP studies
byHamilton et al., Viscidi et al., and Stolt et al., who also included
preabsorption studies [40–42]. We noted a higher BK-VLP IgG
level in individuals who shed BKV serotype 1 compared with
those who shed virus that was not serotype 1. Among those who
shed serotype 1 virus, the individuals who shed subtype 1-b1—
which was used to generate the BK VLP—showed higher levels
of IgG activity. Of note, (sub)serotypes 1-b1 and 1-b2 only differ
by 1 amino acid in the VP1 gene (position 1908). These differ-
ences suggest that the IgG response is highly specific for the re-
Figure 4. Virus-like particle (VLP)–specific IgG levels in serum samples from 400 healthy blood donors evaluated for BK and JC polyomavirus (BKV
and JCV). BK-VLP–specific and JC-VLP–specific IgG levels (A) and IgM levels (B) in samples were plotted against each other, and regression analysis
was performed to check for statistical evidence of cross-reactivity. Note that log scales differ in A and B. C, Comparison of BK-VLP–specific IgG levels
between donors who had BKV serotype 1 in urine and donors who had non-serotype 1 (i.e., serotypes 2–4) BKV in urine. D, BK-VLP–specific IgG levels
in donors with BKV serotype 1 in urine were further compared among BKV subtypes 1a, 1b-1, and 1b-2. Boxes span the interquartile range; the line
within each box denotes the median, and whiskers indicate the minimum and maximum values. *P calculated by Mann-Whitney U test. **P calculated
by Kruskal-Wallis test. OD492, optical density at 492 nm; R2, regression coefficient.
844 ● JID 2009:199 (15 March) ● Egli et al.
spective BKV subtype, leading to underquantification of IgG lev-
els in response to other BKV (sub)types. Another explanation
could be that secondary exposure to BKV subtype 1-b1 is more
prevalent, and therefore the cognate antibody responses are
boosted. Although none of the individuals who shed BKV sub-
types other than 1-b1 were seronegative, our data indicate that
further studies are needed to investigate the diagnostic and
pathogenic relevance of BKV subtype-specific IgG. For JCV,
only a single capsid serotype has been reported.
Urinary polyomavirus shedding among immunocompetent,
healthy blood donors provided a unique opportunity to investi-
gate the architecture of the regulatory NCCR of both BKV and
JCV. In all but 1 case of JCV infection, the BKV and JCV NCCR
were of archetype architecture. Earlier in vitro studies showed
that rearrangements of the NCCR (rr-NCCR) arise rapidly dur-
ing polyomavirus replication [43]. Typically, partial duplica-
tions (insertions) and deletions are found, which confer in-
creased early gene expression and higher replication capacity.
JCV and BKV with rr-NCCR have been detected in vivo in pa-
thology samples of affected brain and transplant tissue, as well as
in the cerebrospinal fluid and blood of patients with PML and
PVAN, respectively [44]. In patients undergoing kidney trans-
plantation, the emergence of rr-NCCR BKV in plasma is associ-
ated with higher plasma BKV loads and more advanced pathol-
ogy both in vivo and in vitro [12, 45, 46]. In healthy individuals,
little data is available on the prevalence of rearranged viruses. In
urine samples from pregnant women, Markowitz et al. found
predominantly archetypal BKV in 18 of 127 samples and pre-
dominantly archetypal JCV in 5 of 76 samples [47]. Thus, our
data support the hypothesis that high-level replication in vitro or
in vivo in severely immunocompromised patients seems to be
linked to the frequent emergence of polyomavirus variants with
rr-NCCR [44].
We could not detect BKV or JCV in plasma. Dolei et al. exam-
ined PBMC DNA from 205 blood donors and 26 workers in a
hematology unit and reported that 21.6% of PBMCs tested pos-
itive for BKV, whereas JCV DNA was found in 0.9% by use of
nested PCR [23]. By contrast, Ling et al., who did not use nested
PCR, failed to detect BKV or JCV DNA in any of 30 blood sam-
ples; noBKVwas found in urine samples but JCVwas detected in
47% of samples and was more common in samples obtained
from individuals40 years old (P  .03) [22]. Thus, we cannot
exclude the possibility that more sensitive PCR protocols might
allow the detection of low levels of polyomavirus DNA, but viral
genome integrity, the cell types involved, and contamination
needs to be addressed to elucidate the potential significance of
such results [48].
In summary, our study provides important baseline data on
polyomavirus infection and viral replication in healthy, immu-
nocompetent individuals. These data indicate significant differ-
ences between BKV and JCV with respect to virus-host interac-
tion and the epidemiology of infection, which may have an
impact on the pathogenesis of infection in immunocompro-
mised patients.
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